Study shows drug combination improves outcome for advanced non-small cell lung cancer
Sunday, May 31, 2009 - 12:28
in Health & Medicine
A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting.
Read the whole article on Physorg
More from Physorg
Related
- Study shows drug combination improves outcome for advanced non-small cell lung cancerSat, 30 May 2009, 11:29:37 EDT
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT
- Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patientsSat, 1 Aug 2009, 15:37:16 EDT
- African American lung cancer patients may have different response to new cancer-fighting drugsWed, 7 Oct 2009, 18:11:47 EDT
- Surgery not necessary for most late-stage colorectal cancersSat, 30 May 2009, 9:49:47 EDT